CeriBell, Inc.
NASDAQ:CBLLMedical - Devices
+$0.25 today
- Market cap
- $995.34M
- Beta
- 0.84
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$1.60
Volume 0.41M
Average 0.29M
CBLL Effect of Forex Changes
Change in reported cash caused by exchange-rate movements on foreign-currency balances.
CeriBell, Inc.NASDAQ: CBLL
Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026
Effect of forex changes outflow grows to $0
Q1 FY2026 effect of forex changes was $0, compared with $0 a year earlier. Trailing-twelve-month effect of forex changes was $0.
Context
- Effect of forex changes amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Effect of forex changes increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly effect of forex changes holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Effect of Forex Changes history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Effect of Forex Changes | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Effect of Forex Changes vs competitors
How CBLL compares with its peers on the latest reported figures
- CBLL's LTM Mar 2026 effect of forex changes of $0 is the 6th largest of the 7 companies compared; the peer median is $1K.
- Effect of forex changes amounts to 0.0% of revenue for CBLL, versus a peer median of 0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $4.13M | -148.9% | — | 0.3% | |
| LTM Mar 2026 | $730K | — | — | 0.7% | |
| LTM Mar 2026 | $88K | +239.7% | — | 0.2% | |
| LTM Mar 2026 | $14K | -80.8% | — | 0.0% | |
| LTM Mar 2026 | $2K | -166.7% | — | 0.0% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CBLL) | $1K | -114.9% | — | 0.1% | |
Competitors are the stored peer set for CBLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (37.16M) | (29.46M) | (40.46M) | (53.41M) |
| Depreciation & Amortization | 497K | 847K | 1.14M | (670K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.93M | 2.68M | 5.41M | 12.22M |
| Change in Working Capital | (3.88M) | (3.7M) | (3.17M) | 633K |
| Accounts Receivables | (3.96M) | (3.43M) | (3.51M) | (4.18M) |
| Inventory | (1.9M) | (1.79M) | (1.07M) | (351K) |
| Accounts Payables | 124K | 309K | 250K | 1.75M |
| Other Working Capital | 1.85M | 1.22M | 1.16M | 3.41M |
| Other Non-Cash Items | 621K | 477K | 2.03M | 418K |
| Operating Cash Flow | (32M) | (29.16M) | (35.04M) | (40.81M) |
| Capital Expenditures | (516K) | (983K) | (1.34M) | (767K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (210.82M) |
| Sales of Investments | 0 | 0 | 0 | 94.2M |
| Other Investing Activities | (883K) | (780K) | (258K) | (755K) |
| Investing Cash Flow | (1.4M) | (1.76M) | (1.6M) | (118.14M) |
| Debt Repayment | (39K) | (3.75M) | 7.91M | 0 |
| Common Stock Issued | 0 | 0 | 188.92M | 5.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 154K | 932K | (304K) | (386K) |
| Financing Cash Flow | 49.81M | (2.82M) | 196.52M | 5.05M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.4M | (33.74M) | 159.88M | (153.89M) |
| Free Cash Flow | (32.52M) | (30.14M) | (36.38M) | (41.58M) |
CeriBell, Inc.
NASDAQ:CBLL
Intrinsic Alpha fair value
Locked
Current Price
$25.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.